Global Biologics Analytical Testing CMO Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Biologics Analytical Testing CMO Market Overview

The Biologics Analytical Testing CMO Market was valued at USD 2.36 billion in 2025 and is projected to reach USD 6.68 billion by 2033, growing at a CAGR of 13.90% from 2026 to 2033. The market is experiencing consistent growth driven by rising demand for outsourced biologics development services, increasing complexity of biologic drug products, and expanding applications across monoclonal antibodies, vaccines, cell therapies, and recombinant proteins.

The growing adoption of biologics and advanced therapies, combined with increasing regulatory requirements for quality, safety, and product characterization, is encouraging pharmaceutical and biotechnology companies to outsource analytical testing activities to specialized contract manufacturing organizations (CMOs). Advanced analytical technologies such as mass spectrometry, chromatography, molecular characterization, and bioassay platforms are improving testing accuracy and efficiency for biologic products. In addition, the expansion of biopharmaceutical pipelines, increasing investments in biologics manufacturing, and the need for scalable and regulatory-compliant testing solutions are accelerating demand for biologics analytical testing CMO services globally.

Key Market Trends & Insights

• North America dominated the Biologics Analytical Testing CMO Market with the largest revenue share of 38.6% in 2025, supported by the strong presence of leading pharmaceutical and biotechnology companies, advanced analytical testing infrastructure, and increasing outsourcing of biologics characterization and quality testing activities to specialized CMOs. The region benefits from high adoption of advanced testing platforms, strict regulatory requirements from agencies such as the FDA, and significant investments in biologics, monoclonal antibodies, vaccines, and cell & gene therapies, strengthening its market leadership.
• The molecular characterization testing segment dominated the market with a 31.4% share in 2025, owing to increasing demand for detailed analysis of biologic molecules, including structural identification, purity assessment, impurity profiling, and characterization of critical quality attributes.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 11.2% from 2026 to 2033, fueled by expanding biopharmaceutical manufacturing capabilities, increasing investments in biologics production, rising outsourcing activities, and growing demand for analytical testing services across China, India, South Korea, and Japan. The expansion of local CDMO infrastructure, government support for biotechnology innovation, and increasing clinical pipeline of biologic therapies are accelerating regional market growth.
• Cell-based assays are projected to be the fastest-growing testing type segment with a CAGR of 10.8% from 2026 to 2033, supported by increasing adoption in biologics development, vaccine testing, biosimilar evaluation, and potency assessment. Growing demand for reliable biological activity testing, advancements in assay technologies, and increasing development of complex biologics such as monoclonal antibodies and cell therapies are driving segment expansion.

Market Size & Forecast

• Global Market Value (2025): USD 2.36 Billion
• Expected Market Value (2033): USD 6.68 Billion
• Forecast CAGR (2026–2033): 13.90%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Biologics Analytical Testing CMO Market Segmentation

Biologics Analytical Testing CMO Market Trends

Trend: Rising Adoption of Advanced Analytical Testing for Complex Biologics Development

The Biologics Analytical Testing CMO Market is witnessing increasing adoption of advanced analytical testing solutions as pharmaceutical and biotechnology companies expand their biologics pipelines, including monoclonal antibodies, recombinant proteins, vaccines, and cell & gene therapies. The growing complexity of biologic molecules has increased demand for specialized testing services such as molecular characterization, protein analysis, cell-based assays, and impurity profiling to ensure product quality, safety, and regulatory compliance. Contract testing organizations are increasingly investing in advanced platforms including mass spectrometry, chromatography, next-generation sequencing, and automated analytical workflows to support faster biologics development. For instance, leading CDMOs and analytical service providers are expanding their biologics testing capabilities to support the increasing number of biologic drug candidates entering clinical and commercial stages, strengthening outsourcing adoption across the pharmaceutical industry.

Biologics Analytical Testing CMO Market Dynamics

Key Market Driver: Increasing Outsourcing of Biologics Analytical Testing by Pharmaceutical and Biotechnology Companies

The rising demand for biologic medicines and the expansion of complex therapeutic pipelines are major factors driving the growth of the biologics analytical testing CMO market. Pharmaceutical and biotechnology companies are increasingly outsourcing analytical testing activities to specialized CMOs to access advanced technologies, reduce development timelines, and manage the high cost associated with in-house laboratory infrastructure. The growing adoption of monoclonal antibodies, biosimilars, vaccines, and cell-based therapies has increased the need for comprehensive analytical characterization, stability testing, and quality control services. According to industry trends, biologics represent a significant share of new drug development pipelines, creating strong demand for external analytical expertise. In addition, regulatory requirements from agencies such as the FDA and EMA for detailed characterization and consistent manufacturing quality are encouraging companies to partner with experienced analytical testing providers.

Key Restraint/Challenge: High Cost and Regulatory Complexity Associated with Advanced Biologics Analytical Testing

A significant challenge in the Biologics Analytical Testing CMO Market is the high investment required for advanced analytical infrastructure, specialized equipment, and skilled scientific expertise. Technologies such as mass spectrometry, chromatography systems, sequencing platforms, and advanced bioassay platforms require substantial capital investment, regular maintenance, and continuous technology upgrades. In addition, biologics testing involves strict regulatory compliance, method validation, data integrity requirements, and complex documentation processes, which can increase operational costs and extend project timelines. Smaller biotechnology companies may face challenges in accessing high-end analytical services due to pricing pressures and the need for specialized expertise. The requirement for consistent quality standards across global markets further adds complexity to outsourcing decisions.

Key Market Opportunity: Expansion of Personalized Medicine, Biosimilars, and Cell & Gene Therapy Testing

The increasing development of personalized medicines, biosimilars, and advanced therapies presents significant growth opportunities for the biologics analytical testing CMO market. The growing pipeline of complex biologics requires specialized analytical approaches for identity testing, potency evaluation, structural characterization, and safety assessment. The rapid expansion of cell and gene therapy programs is creating demand for advanced analytical platforms capable of evaluating critical quality attributes and biological activity. In addition, increasing biosimilar development is driving the need for comparative analytical testing to demonstrate similarity with reference biologic products. For instance, major pharmaceutical companies and CDMOs are expanding analytical service capabilities to support next-generation biologics, while emerging biotechnology hubs in Asia-Pacific are increasing investments in outsourced testing infrastructure, creating new opportunities for market expansion.

Biologics Analytical Testing CMO Market Scope

The biologics analytical testing CMO market is segmented on the basis of testing type and end user.

By Testing Type

On the basis of testing type, the Biologics Analytical Testing CMO Market is segmented into cell-based assays, bioassays, molecular characterization testing, protein characterization testing, microbiological testing, and other analytical testing services. The Molecular Characterization Testing segment dominated the market with a 31.4% share in 2025, owing to increasing demand for detailed analysis of biologic molecules, including structural identification, purity assessment, impurity profiling, and characterization of critical quality attributes. The growing complexity of biologics such as monoclonal antibodies, recombinant proteins, vaccines, and cell & gene therapies has increased the requirement for advanced analytical techniques including mass spectrometry, chromatography, and sequencing-based methods. In addition, stringent regulatory requirements from agencies such as the FDA and EMA for biologics safety, consistency, and quality evaluation are driving pharmaceutical companies to outsource molecular characterization activities to specialized CMOs.

The cell-based assays segment is projected to register the fastest growth at a CAGR of 10.8% from 2026 to 2033, driven by increasing adoption of biologics, vaccine development, and advanced therapies requiring reliable potency and biological activity testing. Cell-based assays are becoming increasingly important for evaluating the functional performance of biologic products, especially monoclonal antibodies, biosimilars, and cell therapies. The expansion of personalized medicine, increasing clinical trials for biologics, and growing investments in automated assay platforms are further accelerating the adoption of cell-based analytical testing services among pharmaceutical companies and biotechnology firms.

By End User

On the basis of end user, the Biologics Analytical Testing CMO Market is segmented into pharmaceutical & biotechnology companies, contract development & manufacturing organizations (CDMOS), research institutes & academic organizations, and clinical research organizations (CROs). The pharmaceutical & biotechnology companies segment dominated the market with a 42.7% share in 2025, supported by increasing outsourcing of biologics analytical testing activities to specialized service providers. Pharmaceutical and biotechnology companies are increasingly relying on CMOs for advanced analytical characterization, quality control testing, stability studies, and regulatory compliance support to reduce development timelines and avoid high infrastructure investments. The growing pipeline of monoclonal antibodies, recombinant proteins, vaccines, and gene therapies is further increasing demand for outsourced analytical testing solutions.

The contract development & manufacturing organizations (CDMOs) segment is expected to witness the fastest growth at a CAGR of 11.5% from 2026 to 2033, driven by the rising demand for integrated biologics development and manufacturing services. CDMOs are expanding their analytical testing capabilities to provide end-to-end solutions covering process development, characterization, validation, and commercial manufacturing support. Increasing partnerships between pharmaceutical innovators and CDMOs, along with growing biologics outsourcing trends across North America, Europe, and Asia-Pacific, are strengthening segment growth. In addition, investments in advanced analytical platforms and regulatory-compliant testing facilities are enabling CDMOs to support complex biologics pipelines and accelerate market expansion.

Biologics Analytical Testing CMO Market Regional Analysis

North America dominated the Biologics Analytical Testing CMO Market and accounted for the largest revenue share of 38.6% in 2025, supported by the strong presence of leading pharmaceutical and biotechnology companies, advanced analytical testing infrastructure, and increasing outsourcing of biologics characterization and quality testing activities to specialized contract manufacturing organizations. The region benefits from high adoption of advanced analytical platforms, stringent regulatory standards from agencies such as the FDA, and significant investments in biologics, monoclonal antibodies, vaccines, and cell & gene therapies. Growing demand for reliable quality testing solutions, increasing biologics pipeline development, and rising partnerships between biotech companies and specialized CMOs are further strengthening North America’s leading position in the global market.

U.S. Biologics Analytical Testing CMO Market Insight

The U.S. biologics analytical testing CMO market is witnessing strong growth due to the presence of a mature biotechnology ecosystem, increasing biologics development activities, and rising demand for outsourced analytical testing services. Pharmaceutical and biotechnology companies are increasingly partnering with CMOs to access advanced testing capabilities such as protein characterization, impurity analysis, stability testing, and biosimilarity assessments. In addition, increasing investments in monoclonal antibodies, vaccines, and cell and gene therapies, along with strict regulatory compliance requirements, are driving demand for specialized analytical testing services across the country.

Europe Biologics Analytical Testing CMO Market Insight

The Europe biologics analytical testing CMO market remains a significant contributor to global revenue, driven by strong pharmaceutical manufacturing capabilities, advanced laboratory infrastructure, and increasing adoption of outsourcing models for biologics development and testing. The region’s focus on regulatory compliance, quality assurance, and development of innovative biologic therapies is supporting market expansion. Increasing investments in biologics manufacturing, biosimilars, and advanced analytical technologies are encouraging pharmaceutical companies to collaborate with specialized CMOs for efficient and reliable testing solutions.

U.K. Biologics Analytical Testing CMO Market Insight

The U.K. biologics analytical testing CMO market is experiencing steady growth, supported by increasing biotechnology research activities, expanding biologics pipelines, and rising demand for outsourced analytical services. The country’s strong life sciences ecosystem and growing focus on advanced therapies are driving adoption of specialized testing solutions for biologic drugs, vaccines, and complex therapeutic products. Furthermore, increasing investments in laboratory automation, advanced characterization techniques, and regulatory-compliant testing platforms are supporting market growth across the U.K.

Germany Biologics Analytical Testing CMO Market Insight

The Germany biologics analytical testing CMO market is expanding steadily due to the country’s strong pharmaceutical industry, advanced research capabilities, and growing biologics manufacturing base. Pharmaceutical companies and biotechnology organizations are increasingly utilizing CMOs for analytical testing services to improve efficiency, reduce development timelines, and ensure compliance with strict quality standards. Continuous advancements in analytical technologies, including chromatography, mass spectrometry, and molecular characterization methods, along with strong focus on biologics innovation, are further driving market growth in Germany.

Asia-Pacific Biologics Analytical Testing CMO Market Insight

The Asia-Pacific biologics analytical testing CMO market is expected to witness rapid growth, with a projected CAGR of 11.2% from 2026 to 2033, driven by expanding biopharmaceutical manufacturing capabilities, increasing outsourcing activities, and rising investments in biotechnology infrastructure across countries such as China, India, South Korea, and Japan. Growing adoption of biologics, biosimilars, and advanced therapies is increasing demand for analytical testing services. In addition, government initiatives supporting biotechnology innovation, expansion of CDMO facilities, and increasing clinical research activities are accelerating regional market growth.

Japan Biologics Analytical Testing CMO Market Insight

The Japan biologics analytical testing CMO market is witnessing consistent growth due to increasing investments in biologics research, advanced healthcare technologies, and pharmaceutical innovation. Biotechnology companies and research institutions are increasingly outsourcing analytical testing activities to specialized providers to support biologics development, quality evaluation, and regulatory submissions. The growing adoption of advanced therapies, rising demand for precision analytical methods, and strong focus on pharmaceutical quality standards are further contributing to market expansion.

China Biologics Analytical Testing CMO Market Insight

The China biologics analytical testing CMO market is growing rapidly, driven by expanding biologics manufacturing capacity, increasing investments in biotechnology research, and rising demand for outsourced analytical testing services. The country’s growing pharmaceutical industry, increasing development of monoclonal antibodies, vaccines, and biosimilars, and expansion of local CDMO infrastructure are supporting market growth. In addition, government support for biotechnology innovation, improving regulatory frameworks, and increasing adoption of advanced analytical technologies are positioning China as one of the fastest-growing markets for Biologics Analytical Testing CMO services globally.

Biologics Analytical Testing CMO Market Share

The Biologics Analytical Testing CMO industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific (U.S.)
• Lonza Group (Switzerland)
• Charles River Laboratories (U.S.)
• Eurofins Scientific (Luxembourg)
• SGS SA (Switzerland)
• Merck KGaA (Germany)
• Sartorius AG (Germany)
• WuXi Biologics (China)
• WuXi AppTec (China)
• Catalent (U.S.)
• Labcorp Drug Development (U.S.)
• ICON plc (Ireland)
• IQVIA Inc. (U.S.)
• Syngene International (India)
• AGC Biologics (U.S.)
• Fujifilm Diosynth Biotechnologies (Japan)
• Samsung Biologics (South Korea)
• BioReliance (U.S.)
• KBI Biopharma (U.S.)
• Alcami Corporation (U.S.)
• Pace Analytical Services (U.S.)
• Intertek Group plc (U.K.)
• Nelson Laboratories (U.S.)
• Charles River Biologics Testing Solutions (U.S.)
• Medpace Holdings Inc. (U.S.)
• GenScript Biotech (China)
• Q2 Solutions (U.S.)
• Pharmaron (China)
• Recipharm (Sweden)
• Rentschler Biopharma (Germany)
• Vetter Pharma (Germany)
• Boehringer Ingelheim BioXcellence (Germany)
• ProBioGen AG (Germany)
• BioIVT (U.S.)
• SGS Life Sciences (Switzerland)Top of FormBottom of Form

Latest Developments in Biologics Analytical Testing CMO Market

• In January 2021, WuXi Biologics announced the expansion of its biologics testing and analytical services capacity in China and Ireland, strengthening its global biosafety testing and characterization capabilities for monoclonal antibodies and other biologics. The expansion included additional GMP-compliant analytical labs to support increasing global demand for outsourced biologics development and quality testing services, reinforcing its position as a leading global CRDMO service provider
• In March 2022, Samsung Biologics announced the expansion of its Songdo Bio Campus in South Korea, adding large-scale biologics manufacturing capacity and enhancing integrated analytical testing and quality control capabilities. The expansion was designed to support end-to-end CDMO services, including cell line development, process development, and GMP analytical testing for global pharmaceutical clients, particularly in monoclonal antibodies and biosimilars
• In July 2023, Lonza announced the expansion of its biologics manufacturing and analytical development capabilities in Visp, Switzerland, focusing on integrated cell line development, process characterization, and advanced analytical testing services. The expansion aimed to strengthen Lonza’s CDMO leadership in biologics, including monoclonal antibodies and cell & gene therapy analytical support, driven by rising outsourcing demand from global pharmaceutical companies
• In February 2024, Catalent announced upgrades to its biologics analytical development and cell line development services across its U.S. and European facilities, enhancing its capabilities in biosimilarity testing, protein characterization, and GMP-compliant analytical workflows. The investment supported increasing demand for outsourced biologics development services, especially in monoclonal antibody and recombinant protein pipelines
• In December 2024, Lonza announced its strategic restructuring to focus more heavily on its core CDMO and biologics contract development services, including advanced analytical testing and specialized modality development. The company also confirmed continued investments in high-value biologics platforms such as integrated biologics and advanced synthesis, strengthening its position in outsourced analytical testing and cell line development services
• In December 2025, Samsung Biologics announced the acquisition of a U.S. biologics production facility from GSK for USD280 million, marking a major expansion of its global manufacturing and analytical service footprint. The facility enhances its capacity for biologics drug substance manufacturing and associated analytical testing services, including biosafety testing, quality control, and characterization for global clients
• In December 2025, global CDMO market analysis reports highlighted continued expansion by Lonza, Samsung Biologics, and WuXi Biologics, emphasizing increased investment in biologics analytical testing, cell line development outsourcing, and biosimilar manufacturing services. The sector continues to benefit from strong demand for outsourced GMP analytical services and increasing biologics pipeline complexity across pharmaceutical companies

SKU-76276